We are live on ! Find out more
RPRX icon

Royalty Pharma
RPRX

447 hedge funds and large institutions have $10.1B invested in Royalty Pharma in 2025 Q1 according to their latest regulatory filings, with 84 funds opening new positions, 160 increasing their positions, 149 reducing their positions, and 50 closing their positions.

New
Increased
Maintained
Reduced
Closed

160% more call options, than puts

Call options by funds: $89M | Put options by funds: $34.2M

68% more first-time investments, than exits

New positions opened: 84 | Existing positions closed: 50

22% more capital invested

Capital invested by funds: $8.21B → $10.1B (+$1.84B)

7% more funds holding

Funds holding: 416 → 447 (+31)

2.07% more ownership

Funds ownership: 72.43% → 74.49% (+2.1%)

7% more repeat investments, than reductions

Existing positions increased: 160 | Existing positions reduced: 149

22% less funds holding in top 10

Funds holding in top 10: 9 → 7 (-2)

Holders
447
Holders Change
+31
Holders Change %
+7.45%
% of All Funds
5.99%
Holding in Top 10
7
Holding in Top 10 Change
-2
Holding in Top 10 Change %
-22.22%
% of All Funds
0.09%
New
84
Increased
160
Reduced
149
Closed
50
Calls
$89M
Puts
$34.2M
Net Calls
+$54.8M
Net Calls Change
+$39.9M

Top Buyers

1
Fidelity Investments
Fidelity Investments
Massachusetts
+$413M
2
CIA
Caledonia Investments (Australia)
Australia
+$162M
3
Victory Capital Management
Victory Capital Management
Texas
+$83.8M
4
Morgan Stanley
Morgan Stanley
New York
+$47.5M
5
Los Angeles Capital Management
Los Angeles Capital Management
California
+$33M

Top Sellers

1
Adage Capital Partners
Adage Capital Partners
Massachusetts
-$340M
2
Millennium Management
Millennium Management
New York
-$66.8M
3
SGA
Siguler Guff Advisers
New York
-$60.4M
4
Deutsche Bank
Deutsche Bank
Germany
-$56.3M
5
Viking Global Investors
Viking Global Investors
Connecticut
-$52.1M
Name Holding Trade Value Shares
Change 		Change in
Stake
WorldQuant Millennium Advisors
201
WorldQuant Millennium Advisors
New York
$1.6M -$17.7M -558,922 -92%
Baird Financial Group
202
Baird Financial Group
Wisconsin
$1.59M -$349K -11,010 -18%
TAF
203
Tredje AP-fonden
Sweden
$1.59M – – –
CCIA
204
Campbell & Co Investment Adviser
Maryland
$1.58M -$1.4M -44,320 -47%
PAM
205
Panagora Asset Management
Massachusetts
$1.54M -$451K -14,226 -22%
NAM
206
Nissay Asset Management
Japan
$1.52M +$6.21K +196 +0.4%
IIM
207
INTECH Investment Management
Florida
$1.49M +$442K +13,951 +41%
Mariner
208
Mariner
Kansas
$1.47M +$674K +21,275 +82%
SSA
209
Schonfeld Strategic Advisors
New York
$1.45M -$1.03M -32,590 -41%
Twin Tree Management
210
Twin Tree Management
Texas
$1.39M -$21.2K -668 -1%
Fidelity International
211
Fidelity International
Bermuda
$1.36M -$154K -4,856 -10%
Creative Planning
212
Creative Planning
Kansas
$1.33M +$302K +9,521 +29%
SMDAM
213
Sumitomo Mitsui DS Asset Management
Japan
$1.3M +$432K +13,615 +48%
Public Employees Retirement Association of Colorado
214
Public Employees Retirement Association of Colorado
Colorado
$1.27M – – –
Axa
215
Axa
France
$1.27M -$3.65M -115,188 -74%
X
216
Xponance
Pennsylvania
$1.25M +$45.5K +1,437 +4%
Lazard Asset Management
217
Lazard Asset Management
New York
$1.25M +$529K +16,694 +71%
BPCE
218
Bank Pictet & Cie (Europe)
Germany
$1.25M -$317K -10,000 -20%
DADC
219
D.A. Davidson & Co
Montana
$1.17M -$333K -10,511 -22%
MGP
220
Metis Global Partners
California
$1.15M +$33.6K +1,060 +3%
FAM
221
Formidable Asset Management
Ohio
$1.15M -$1.14K -36 -0.1%
MNA
222
Manning & Napier Advisors
New York
$1.14M -$1.41M -44,505 -55%
AAB
223
ABN AMRO Bank
Netherlands
$1.13M +$1.15M +36,344 New
GL
224
Graypoint LLC
New York
$1.1M – – –
Janus Henderson Group
225
Janus Henderson Group
United Kingdom
$1.07M – – –
7 8
9
10 11

RPRX Hedge Fund Activity: Q1 2025 in Review

447 of the 7,457 institutional investors tracked by Wall St. Rank reported a position in Royalty Pharma (RPRX) for Q1 2025, worth a combined $10.1B — up 22% from $8.21B a quarter earlier.

Buyers outnumbered sellers: 84 funds opened new RPRX positions and 50 closed out — a net gain of 34 holders — while 160 added to existing stakes and 149 trimmed.

The largest buyer was Fidelity Investments, adding an estimated $413M. The largest seller was Adage Capital Partners, cutting an estimated $340M.

  • 447 institutional investors held Royalty Pharma (RPRX) as of Q1 2025, up from 416 in Q4 2024.
  • Funds reported $10.1B of Royalty Pharma stock for Q1 2025, up 22% quarter-over-quarter.
  • 84 funds opened new Royalty Pharma positions in Q1 2025 and 50 closed out, a net change of +34 holders.
  • The largest Royalty Pharma buyer in Q1 2025 was Fidelity Investments, an estimated $413M added.
  • The largest Royalty Pharma seller in Q1 2025 was Adage Capital Partners, an estimated $340M sold.

Based on aggregated 13F filings for Q1 2025.